Although the genetic causes of hypertrophic cardiomyopathy (HCM) are widely recognized, considerable lag in the development of targeted therapeutics has limited interventions to symptom palliation. This is in part attributable to an incomplete understanding of how point mutations trigger pathogenic remodeling. As a further complication, similar mutations within sarcomeric genes can result in differential disease severity, highlighting the need to understand the mechanism of progression at the molecular level. One pathway commonly linked to HCM progression is calcium homeostasis dysregulation, though how specific mutations disrupt calcium homeostasis remains unclear.
H
ypertrophic cardiomyopathy (HCM) is typically characterized by diastolic dysfunction with variable cardiac remodeling and, in some cases, sudden cardiac death. 1, 2 In a landmark study in 1990 by Geisterfer-Lowrance et al, 3 the first genetic cause of HCM was identified linking mutations in sarcomeric genes to disease. Since then, genetic studies have identified mutations in at least 20 different genes linked to HCM, with >450 mutations found in genes that encode for sarcomeric proteins. 4, 5 However, although the genetic causes are well described, a lack of high-resolution understanding of the natural history of disease has limited the development of optimal therapeutic interventions (reviewed by Spoladore et al 6 ). Thus, it is imperative to identify the pathological triggers and subsequent downstream responses to specifically target molecular mechanisms in patients and alter the natural history of pathogenic remodeling in HCM.
One frequently described pathway underlying disease progression in sarcomeric HCM is disruption of calcium homeostasis, a critical component in the maintenance of excitation-contraction coupling within the myocyte. [7] [8] [9] Characteristic features of this dysregulation include increased resting calcium levels, reduced calcium transients, and altered expression of calcium handling machinery, all of which likely contribute to the progressive diastolic dysfunction seen in patients. [10] [11] [12] [13] Additionally, HCM mutations are commonly characterized by an increase in the calcium sensitivity of force generation, adding to the uncoupling of excitation and contraction within the myocyte. [14] [15] [16] Current therapies for HCM are primarily aimed at treating the symptoms of diastolic dysfunction and outflow tract obstruction, including L-type calcium channel blockers such as diltiazem hydrochloride and β-blockers. These interventions are used for their negative ionotropic and chronotropic effects on the myocardium to allow for increased left ventricular filling in the context of chronically elevated filling pressures. Interestingly, a recent clinical trial described a gene-specific response to treatment with diltiazem-HCl, suggesting 2 potential mechanisms of early disease: calcium-dependent progression versus calcium-independent progression. 17, 18 One well-characterized myocellular regulator of calcium homeostasis is calmodulin kinase II (CaMKII; δ and γ-cardiac isoforms), a calcium-dependent, multifunctional kinase that phosphorylates multiple excitation-contraction coupling-associated proteins. Autonomous activity of the kinase, conferred primarily via autophosphorylation that renders the kinase calciumindependent, has been implicated in heart failure and arrhythmogenesis, and recently in late-stage clinical HCM. 13, [19] [20] [21] Although these studies implicate unregulated CaMKII in mature disease, the mechanisms by which myofilament mutations activate the kinase and the role of constitutive CaMKII activation in early disease progression remain to be elucidated.
To investigate mutation-specific mechanisms of calcium dysregulation and downstream CaMKII activation, we used 2 individual transgenic mouse models of clinically relevant HCM that carry mutations found within the myofilament protein cardiac troponin T (Arg92Leu [R92L] and Arg92Trp [R92W]). [22] [23] [24] Despite the similarities between these mutations, including an identical charge loss at residue 92, patients harboring these mutations present with differential phenotypes and disease severities. Specifically, R92L leads to overt left ventricular hypertrophy but a low incidence of sudden cardiac death, whereas R92W patients exhibit a lesser degree of left ventricular hypertrophy but an increased risk of sudden cardiac death. 22, 23 Previous in vitro and in vivo characterization of the mutations indicated a mutation-specific, temporal dysregulation in calcium handling machinery and CaMKII activation. 12, 25 To test the role of calcium dysregulation in disease progression, we have targeted downstream calcium handling in the R92L and R92W transgenic mice via 2 modes of early intervention in calcium regulation: genetic inhibi-
Clinical Perspective
What Is New?
• Although calcium homeostasis dysregulation contributes to progression in hypertrophic cardiomyopathy, the earliest mechanisms by which this dysregulation occurs are not well understood.
• We report an increase in autoactivated calciumdependent calmodulin kinase II (CaMKII) in 2 clinically relevant hypertrophic cardiomyopathy (HCM) mouse models, whereby only the calcium-dependent mutation exhibited a blunting of disease progression at the molecular and whole heart level when CaMKII activity was partially inhibited.
• The L-type calcium channel blocker, diltiazem-HCl, commonly used in clinical management of HCM, elicited a mutation-specific delay of diastolic dysfunction but no concomitant effects on cardiac remodeling.
What Are the Clinical Implications?
• Understanding the primary molecular mechanisms of disease for individual groups of mutations is necessary for improved interventions targeted at delaying or preventing HCM progression in genotyped cohorts.
• While CaMKII activity plays a role in physiological calcium homeostasis, early, aberrant autoactivation of the kinase may be a potential therapeutic target for calcium-dependent HCM progression.
• As autonomous CaMKII activity has also been implicated in heart failure and arrhythmogenesis, improved therapies targeted to the activated kinase are being actively investigated. channel activity. We monitored functional and morphological effects in response to the treatments over time.
We observed a recovery of diastolic function in R92W animals only with diltiazem-HCl treatment, but no effects on left ventricular or atrial remodeling. Alternatively, we report an early, mutation-specific activation of constitutively activated CaMKII that, when targeted, led to functional recovery and blunted atrial remodeling in R92W animals only, suggesting an early role of CaM-KII in calcium-dependent HCM progression. Together, these data highlight the need to define the molecular progression to disease to implement more precise therapeutic options for patients with sarcomeric HCM.
METHODS
All chemicals were obtained from Sigma-Aldrich (St Louis, MO) unless otherwise noted. Treatment of all animals was in accordance with the National Research Council Guide for the Care and Use of Laboratory Animals using protocols approved by the Institutional Animal Care and Use Committee at the University of Arizona. The data, methods, and study materials will be made available on request to the corresponding author for the purposes of reproducing the results or replicating the procedures.
Generation of Transgenic Animals
Generation of transgenic cardiac troponin T R92L and R92W and AC3-I animals have previously been described. 24, 26 AC3I animals were backcrossed into C57Bl/6 background to at least F12. These mice were bred to the R92L and R92W lines to obtain the experimental genotypes: R92L, R92W, AC3I, and AC3I/R92L, and AC3I/R92W. All expected Mendelian ratios were obtained. Nontransgenic siblings from each cross were used as controls.
Western Blot Analysis
Quantitative Western blot analysis of ventricular homogenates was performed as previously described, 12 with slight modification. In brief, excised hearts were trimmed of atrial tissue and homogenized and sonicated on ice in a buffer containing 10 mmol/L imidazole (pH 7.0), 300 mmol/L sucrose, 10 mmol/L sodium azide, 1 mmol/L EDTA, 0.3 mmol/L phenylmethylsulfonyl fluoride, and 0.5 mmol/L dithiothreitol (Thermo Scientific, Waltham, MA). Total protein content was determined via the Pierce BCA Protein Assay kit (Thermo Scientific) using BSA as a standard. Standard methods of SDS-PAGE were used for protein separation. Homogenate was transferred to a 0. ) for optimal linear range assessment. The triplet bands present in the total CaMKIIδ represent the known splice isoforms of CaMKIIδ 27 and were quantified together to calculate total CaMKIIδ levels. Blots probing for p-Thr 17 PLB, p-Ser16 PLB, and total PLB were normalized to calsequestrin levels. Percent phosphorylation was calculated by determining the ratio of normalized phosphorylated protein to normalized total PLB protein.
Echocardiography
Echocardiography was performed using a Vevo 2100 HighResolution Imaging System (Visual-Sonics, Toronto, Canada) with an MS550D scan head designed for murine cardiac imaging. After anesthetic induction in 3% isoflurane, mice were placed in a supine position on a heated platform for echocardiography. Body temperature was maintained at 37°C and anesthesia was maintained with 1.5% isoflurane (USP, Phoenix, AZ) in 100% oxygen. Imaging was performed at a depth setting of 1 cm. Images were stored as digital cine loops for off-line calculations. Standard imaging planes, M-mode, Doppler, and functional calculations were obtained according to American Society of Echocardiography guidelines. Chamber dimensions (left ventricular systolic and diastolic dimensions), posterior wall thickness, and cardiac function via fractional shortening were assessed from M-mode recordings. Doppler imaging was obtained from an apical 4-chamber view to assess left ventricular filling and tissue velocity of the septal mitral annulus. Researchers were blinded to genotype and treatment in data collection and analysis.
Cardiac Morphology
Hearts were excised from anesthetized mice (0.5% isoflurane) and rinsed with PBS. Aorta and pulmonary vessels were removed, and semidry heart weights were collected. The atrial tissue was then removed and weighed. Ventricular tissue was used fresh (SR calcium uptake assay) or immediately flash-frozen in liquid nitrogen and stored at −20°C.
Measurement of SR Calcium Uptake

SR Ca
2+ uptake was measured as previously described. 28 In brief, calcium uptake rate was calculated from fresh ventricular homogenate over a range of Ca 2+ concentrations in a buffer containing 5 mmol/L MgATP
, 40 mmol/L imidazole, 10 mmol/L creatine phosphate, 0.5 mmol/L EGTA, 5 mmol/L potassium oxalate, 5 mmol/L sodium azide, 10 mmol/L procaine, 0.03 mmol/L ruthenium red, and calcium varying from pCa 8 to 5. Sodium azide inhibited calcium uptake by the mitochondria, while ruthenium red and procaine inhibited calcium release from the SR. After a 2-minute preincubation of the assay buffer containing 150 μCi/mL 45 
Ca
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(Perkin Elmer, Waltham, MA) at 37°C, ventricular homogenate was incubated with continuous stirring. After 2 minutes, the reaction was stopped by filtration through a 0.45-μm Millipore filter and washed with cold buffer containing 20 mmol/L Tris and 2 mmol/L EGTA, pH 7.0. Total protein content was determined via the Pierce BCA Protein Assay. The total vesicular calcium uptake was calculated by determining the amount of 45 Ca bound to the Millipore filters (Thermo Scientific) via a liquid scintillation counter. The following equation was used to determine the SR Ca 2+ uptake rate: Ca 2+ Uptake=nmol Ca × (counts per minute/(specific activity x 5) x 1/mg protein in 300 µL) x 0.5.
Diltiazem Hydrochloride Treatment
Two-month-old male nontransgenic, cardiac troponin T R92L, and R92W mice were randomized to treatment with diltiazem hydrochloride (US Pharmacopeia, Rockville, MD) via their drinking water at an approximate dosage of 1.8 mg/d (450 mg/L of water). 29 The mice remained on a constant dosage for 3 months, with treatment water changed every 2 days.
Statistical Analysis
All values are reported as mean±SEM and were calculated in GraphPad Prism7 (San Diego, CA). Two-way ANOVA analysis with Dunnett multiple comparison and Sidak multiple comparison corrections were used to determine statistical significance for genotype and age, respectively, in CaMKII phosphorylation levels. Two-way ANOVA analysis with Dunnett multiple comparison correction was used to determine statistical significance in cardiac function and morphology with CaMKII inhibition. One-way ANOVA with Dunnett multiple comparison test was used to determine the significance of genotype within each age group. Two-way ANOVA with Sidak multiple comparisons and Tukey multiple comparisons tests were used to determine the effects of age and genotype, respectively, for SERCA2a levels. In the diltiazemHCl study, a 2-way ANOVA analysis with Dunnett multiple comparisons and Sidak multiple comparisons corrections were used to determine statistical significance for genotype and treatment, respectively. A P value of less than 0.05 was accepted as statistically significant.
RESULTS
Mutation-Specific Early Activation of Autonomous CaMKII May Play a Role in Disease Progression
The increased phosphorylation of phospholamban at site Thr17 previously observed in R92W animals by Guinto et al 12 suggested a mutation-specific increase in CaMKII activity. Thus, we investigated autonomous activation of CaMKII at 2 time points ( Figure 1A) . Levels of phosphorylated CaMKII (pThr 286/287) suggested a trending decrease at 2 months in R92W animals, whereas R92L animals showed no change in CaMKII phosphorylation ( Figure 1B) . By 6 months, R92W animals exhibited an increase in autoactivation of CaMKII as reported by an increase in phosphorylation of CaMKII ( Figure 1B) and an age-dependent increase in %phosphorylation of CaMKII ( Figure 1D ). R92L animals exhibited an increase in phosphorylation of CaMKII ( Figure 1B ) that was coupled to an age-dependent increase in total CaMKII levels ( Figure 1C ). This early, mutation-specific increase in %phosphorylation of CaMKII supports a potential molecular trigger that contributes to HCM pathogenesis and progression.
Mutation-Specific Improvement in Diastolic Function and Cardiac Remodeling With Inhibition of CaMKII
We next sought to understand the role of CaMKII in disease progression via a small, cardiac-specific peptide competitive inhibitor (AC3I) targeted against the autoactivated state of the kinase.
26 R92W and R92L lines were crossed to mice expressing the AC3I peptide (40% CaMKII inhibition 26 ) to obtain continuous partial inhibition of autonomous CaMKII in our models. To determine the effects of activated CaMKII inhibition on diastolic function, 2-dimensional echocardiography was performed on mice at 2 and 6 months ( Figure 2A ). R92L and R92W animals exhibited early diastolic dysfunction (E/E´) that was unaffected by CaMKII inhibition in R92L and R92W animals ( Figure 2B ). This dysfunction was primarily caused by a decrease in mitral annulus tissue velocity (E´; Figure IB in the online-only Data Supplement), indicating increased tissue stiffness in these animals. This functional index was coupled to an early increase in atrial mass in all genotypes ( Figure 2C ), consistent with increased left ventricular filling pressures. At 6 months, CaMKII inhibition had no effect on diastolic dysfunction or atrial enlargement in the R92L animal ( Figure 2B and 2C) . In contrast, CaMKII inhibition improved diastolic function and blunted the progression of atrial remodeling in R92W mice ( Figure 2B and 2C). This recovery in diastolic function was driven by a reduction in mitral annulus tissue stiffness in the R92W animals with CaMKII inhibition (Figure IB in the onlineonly Data Supplement). Systolic function (% fractional shortening) was improved only in R92W animals with inhibition of CaMKII activity, whereas nontransgenic and R92L animals exhibited hypersystolic function with CaMKII inhibition as compared with their respective controls (Table) . This increased systolic function is likely the result of increased left ventricular wall thickness (diastole; WT d ; mm) seen in the nontransgenic animals with CaMKII inhibition. In contrast, R92L and R92W animals showed no change in WT d with CaMKII inhibition as compared with their uninhibited controls. Of note, left ventricular internal chamber dimension (mm) was decreased in CaMKII-inhibited R92L animals at 2 and 6 months (Table) . These data suggest a mutation-specific improvement and blunting of disease progression over time with inhibition of CaMKII activity. A primary role of myocellular CaMKII is to maintain calcium homeostasis. We investigated the role of CaM-KII inhibition on myocellular calcium handling at the level of the SR. SR calcium uptake rate was measured in ventricular homogenates in 2-and 6-month animals over a range of calcium concentrations as a surrogate of SERCA2a activity ( Figure 3) . As previously reported, R92L animals showed no change in SERCA2a activity over time whereas R92W animals exhibited a recovery of SERCA2a function by 6 months (Figures 3A and  3B) . 12 Inhibition of CaMKII activity led to a significant, early decrease in maximum SERCA2a uptake rate (V Max ) in all genotypes at 2 months ( Figure 3B ). At 6 months, both nontransgenic and R92L animals maintained a reduction in V max with CaMKII inhibition ( Figure 3B ). In contrast, R92W animals recovered SERCA2a function to normal levels despite the maintained CaMKII inhibition. SERCA2a levels were unchanged in R92L and R92W animals expressing CaMKII inhibition as compared with nontransgenic animals at 2 and 6 months, whereas an age-dependent increase in SERCA expression was observed in nontransgenic and R92L animals express- A, Representative Western blot of autoactivated CaMKII levels at 2 months (left) and 6 months (right). p-CaMKII and total CaMKII were detected at 56 kD. The triplet bands in total CaMKII correspond to the known splice isoforms (kDa indicated). 27 Triplicate samples for each genotype are indicated (1-3) . B, Quantification of phosphorylation levels of CaMKII at 2 months (nontransgenic [NT], n=5; R92L, n=6; R92W, n=5) and 6 months (NT, n=6; R92L, n=6; R92W, n=6). C, Quantification of total levels of CaMKII at 2 months (NT, n=5; R92L, n=6; R92W, n=5) and 6 months (NT, n=6; R92L, n=6; R92W, n=6). D, The ratio of phosphorylated CaMKII to total CaMKII was calculated to determine %phosphorylation at 2 months and 6 months. All samples were normalized to total protein using the Revert total protein dye (LICOR). *P≤0.05, **P≤0.01 vs NT; † †P≤0.01, † † †P≤0.001 vs 2 months.
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ing CaMKII inhibition only ( Figure II in the online-only Data Supplement). SR calcium sensitivity (pCa50) was unchanged in all animals ( Figure III in the online-only Data Supplement).
To couple these functional measurements of SERCA activity to its regulation by PLB, we investigated the phosphorylation status of PLB by CaMKII (Thr-17) via Western blot analysis ( Figure 4A ). R92W animals exhibited a significant increase (≈70%) in phosphorylation of Thr-17 PLB from 2 to 6 months ( Figure 4A and 4D) , similar to previous reports. 12 This age-dependent increase in Thr17 phosphorylation was blunted by CaM-KII inhibition in the R92W animals ( Figure 4B and 4D) . Although the levels of Thr-17 phosphorylation were not reduced in these animals, an increase in total PLB levels resulted in a reduction in %phosphorylated Thr-17/PLB ( Figure 4C and 4D) . These findings were also observed in R92L and nontransgenic animals expressing CaMKII inhibition ( Figure 4B through 4D) . Of note, R92L mice exhibited a trending increase in %phosphorylation of Thr-17/PLB (P=0.08, Figure 4D ), although this change was driven by a trending reduction in PLB levels (Figure 4C) . 12 Partial inhibition of autoactivated CaMKII resulted in a trending increase in Ser-16 phosphorylation in all genotypes (data not shown), similar to earlier reports. 26 This increase in phosphorylation of Ser-16 via protein kinase A is uncoupled from an increase in SERCA activity, suggesting insufficient recovery of PLB regulation via β-adrenergic activation.
Diltiazem Hydrochloride Treatment Improves Diastolic Function in CalciumDependent HCM Progression
To determine the effects of targeting calcium handling with a commonly used clinical intervention, R92L and R92W animals were treated with diltiazem-HCl. Diltiazem treatment had no effect on diastolic function (E/ E´) in nontransgenic animals, whereas R92L animals exhibited a trending increase in diastolic dysfunction independent of treatment ( Figure 5B ). This progression of diastolic dysfunction in R92L animals resulted from a reduction in the mitral annular tissue velocity ( Figure IV in the online-only Data Supplement), indicating increased tissue stiffness in these animals despite treatment. In contrast, R92W animals exhibited a blunting of diastolic dysfunction progression with diltiazem treatment (Figure 5B ) attributable to a blunting of mitral annular tissue velocity as compared with untreated R92W mice ( Figure IV in the online-only Data Supplement). This functional measure was compared with atrial mass as a morphological index of decreased left ventricular fill- , n=9; R92L, n=8; R92W, n=5; gray bars, CaMKII inhibition, NT, n=10; R92L, n=10; R92W, n=4), and 6 months of age (black bars, NT, n=13; R92L, n=5; R92W, n=9; gray bars: CaMKII inhibition, NT, n=6; R92L, n=8; R92W, n=7). C, Atrial mass in animals at 2 months (black bars, NT, n=8; R92L, n=4; R92W, n=9; gray bars, CaMKII inhibition, NT, n=5; R92L, n=7; R92W, n=9) and 6 months of age (black bars, NT, n=6; R92L, n=9; R92W, n=10; gray bars, CaMKII inhibition, NT, n=6; R92L, n=7; R92W, n=6 Figure 5C ). 30 Diltiazem treatment had no effect on atrial mass in either genotype, as both R92L and R92W animals exhibited a significantly increased atrial mass independent of treatment. This maintained increase in atrial mass in the R92W animals suggests an uncoupling of the remodeling associated with elevated filling pressures and improved diastolic function measured in the treated animals. Left ventricular remodeling was measured via 2-dimensional echocardiography (Table I in NT, n=7; R92L, n=4; R92W, n=5) and 6 months (black lines, NT, n=8; R92L, n=4; R92W, n=4; gray lines, CaMKII inhibition, NT, n=9; R92L, n=4; R92W, n=4). B, Quantification of maximum SERCA2a activity (V max ) at 2 months (black bars, NT, n=10; R92L, n=5; R92W, n=5, gray bars, CaMKII inhibition, NT, n=7; R92L, n=4; R92W, n=5) and 6 months (black bars, NT, n=8; R92L, n=4; R92W, n=4; gray bars, CaMKII inhibition, NT, n=9; R92L, n=4; R92W, n=4). *P≤0.05, ****P≤0.0001 vs NT-CaMKII inhibition; †P≤0.05, † †P≤0.01 vs 2 months.
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vious reports, 24 which was unchanged with diltiazem treatment. There was no effect of diltiazem-HCl treatment on left ventricular internal chamber dimensions (diastole; LVID d ) in either genotype whereby both R92L and R92W animals exhibited an early, maintained decrease in LVID d independent of treatment. Thus, diltiazem treatment led to a mutation-specific improvement in diastolic function with no effect on left ventricular remodeling in either genotype.
DISCUSSION
Longitudinal studies in patients expressing HCM mutations describe distinct patterns of disease pathogenesis, highlighted in cases of similar point mutations shown to have varying degrees of severity. Although the precise link between myofilament mutations and late-stage left ventricular pathology is not well understood, 1 commonly described pathway in HCM progression is calcium homeostasis dysregulation. We and others have identified mutation-specific alterations in the rate of calcium release from the thin filament as a potential trigger to calcium dysregulation. 10, 15, 25, [31] [32] [33] [34] [35] Although these alterations in myofilament calcium buffering provide a potential screening method to predict derangements in calcium handling, the activated downstream myocellular response(s) that are initiated remain poorly defined.
We investigated this mutation-specific pathogenesis via early intervention in 2 closely related, well-characterized HCM mutations shown to have differential calcium handling. 12, 14, [22] [23] [24] [25] We describe a significant age-dependent increase in autoactivation of CaMKII in the calcium-dependent R92W animals. When this kinase activity was targeted via a partial CaMKII inhibitor (AC3I) 26 , R92W animals exhibited a blunted disease progression, characterized by a reduction in diastolic dysfunction and atrial remodeling. Alternatively, despite an increase in autoactivation of CaMKII over time, R92L animals showed no change in disease progression with CaMKII inhibition. This lack of response in the R92L animals suggests a highly specific, early role of autonomous CaMKII activity in sarcomeric HCM.
CaMKII exists in equilibrium between inactivated, activated, and autoactivated states whereby calciumcalmodulin is required for transition into the activated state and subsequent autoactivation. Given that calcium homeostasis is a dynamic, tightly regulated process in the myocyte, it follows that an increase in autonomous CaMKII is likely the result of calcium homeostasis dysregulation. Moreover, autonomous CaMKII activity has been implicated in heart failure and ar- 6 months (right) . B, Quantification of p-Thr17 PLB at 2 months (black bars, nontransgenic [NT], n=5; R92L, n=6; R92W, n=5; gray bars, CaMKII inhibition, NT, n=5; R92L, n=6; R92W, n=7) and 6 months (black bars, NT, n=6; R92L, n=6; R92W, n=6; gray bars, NT, n=7; R92L, n=5; R92W, n=6). C, Quantification of total PLB (25 kDa) at 2 months (black bars, NT, n=5; R92L, n=6; R92W, n=5; gray bars, CaMKII inhibition, NT, n=5; R92L, n=6; R92W, n=7) and 6 months (black bars, NT, n=6; R92L, n=6; R92W, n=6; gray bars: NT, n=7; R92L, n=5; R92W, n=6). D, Ratio of pThr17 to total PLB levels at 2 months and 6 months of age. All samples were normalized to calsequestrin (55 kDa). *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0. ORIGINAL RESEARCH ARTICLE rhythmogenesis. 13, 19, 21 In human myectomy samples from mature HCM, increased diastolic calcium levels and altered calcium transients were linked to autoactivation of CaMKII. 13 The authors postulated the constitutively activated kinase to be a fundamental link between the HCM mutations and the electrochemical alterations in myocellular excitation-contraction coupling, contributing to the late-stage phenotype. These findings were expanded on by Helms et al, 21 who reported an increase in autonomous CaMKII activity only in myectomy samples from patients with sarcomericpositive HCM. Together, these studies position CaM-KII as a potential nodal point in the pathogenesis of mature HCM.
We investigated the role of the kinase in early molecular disease progression in our HCM murine models. Partial inhibition of the increase in autoactivated CaMKII led to sustained improvement in SERCA activity in the R92W animals. Of note, loss of SERCA function resulting from reduced expression is commonly associated with disease progression in heart failure and cardiomyopathies, 13, 21 leading to clinical trials aimed at restoring these levels via gene therapy. [36] [37] [38] [39] Interestingly, despite mutation-specific alterations in SERCA activity, we report no change in levels of SERCA2a in the R92W animals expressing CaMKII inhibition. Thus, these findings underscore the importance of posttranslational modification of PLB (ie, CaMKII phosphorylation) and its regulation of SERCA2a function and myocyte calcium homeostasis.
The improved calcium handling seen in the R92W animals expressing CaMKII inhibition was coupled to recovery of diastolic function and reduced atrial remodeling over time. Clinically, left atrial enlargement is a sensitive measurement of increased left ventricular filling pressures as seen in diastolic dysfunction and is considered a marker of severe, long-standing dysfunction. 30 Moreover, atrial enlargement is often a precursor of atrial fibrillation in HCM and a critical target for therapeutic intervention. 40 We hypothesize that the resulting mechanism of disease blunting with CaM-KII inhibition in these animals is 2-fold: a reduction 
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in left ventricular stiffness resulting from the recovery of myocellular calcium handling and the loss of offtarget kinase activity within the myocyte. These data highlight the necessity to modulate the levels of CaM-KII within a tolerable range for proper cardiovascular function. Specifically, a decrease in activation seemingly disrupts myocellular calcium handling as seen in the R92W animals at 2 months, whereas an unregulated increase in autoactivation is implicated in disease progression. 13, 19, 21, 26 Thus, CaMKII inhibition may be an advantageous option for early clinical intervention in calcium-dependent HCM progression.
Notably, inhibition of autoactivated CaMKII had no effect on left ventricular remodeling in R92W animals. As previously reported, R92W mice exhibited a minimal change in left ventricular wall thickness over time. This lack of remodeling suggests negligible activation of the nuclear splice-isoform of CaMKII (CaMKII B ) that has been implicated in initiation of the hypertrophicinducing MEF2 signaling cascade. 41 In support, Helms et al 21 did not observe an increase in levels of CaM-KII B or the MEF2 pathway in mature sarcomeric-positive HCM tissue despite increased autoactivation of CaMKII. Thus, our results suggest a cytoplasm-specific increase in CaMKII activity to restore myocellular calcium handling, but linked to pathogenesis over time.
R92L animals also exhibited an increase in phosphorylation of CaMKII at 6 months. In contrast to R92W animals, inhibition of autoactivated CaMKII led to progressive left ventricular remodeling and supranormal systolic function in the calcium-independent R92L animals as compared with their uninhibited controls. As such, these data indicate a negative response with early intervention targeted to CaMKII activity in these animals. It is likely that the measured increase in autonomous CaMKII activation in R92L animals was a later compensatory response to disease as seen clinically, 21 rather than a primary mechanism of progression.
The reported alterations in function and morphology seen with CaMKII inhibition in nontransgenic and R92L animals likely result from the measured reduction in normal SERCA activity. Of note, we observed an uncoupling of SERCA function and phosphorylation of Thr-17 PLB in nontransgenic and R92L animals with CaMKII inhibition. Previous studies have indicated an uncoupling of these 2 systems whereby increased CaMKII-mediated phosphorylation of PLB did not improve SERCA activity in human myectomy samples. 13, 21 The authors speculated that this resulted from the use of mature disease samples, at the end point of disease pathogenesis when loss of SERCA protein expression is thought to regulate the functional deficit observed. We report normal SERCA levels in R92L animals expressing CaMKII inhibition, in agreement with previously reported values for AC3I animals 26 and the R92L-alone animals. 12 Interestingly, the age-dependent increase in SERCA2a levels was insufficient to recover SERCA function in the R92L animals. Further studies are necessary to determine the precise mechanism of uncoupling that governs the failed compensatory response to restore calcium homeostasis in these animals. Nevertheless, these data highlight the detrimental effects of intervening in an unaltered pathway, potentially exacerbating disease progression. Thus, we hypothesize a physiological role of autonomous CaMKII activity in myocellular calcium handling that is required for normal cardiac function over time.
We postulate a nodal role of autoactivated CaMKII in early HCM progression that is specifically and precisely initiated by individual myofilament mutations (Figure 6 ). In the case of the R92W mutation, the observed increase in calcium release from mutated thin filaments would lead to reduced calcium buffering capacity of the myofilament, triggering persistent increased resting calcium levels. 12 This increase in free calcium could potentially lead to local activation of CaMKII and acute improvements in myocellular calcium homeostasis. The continued presence of the myofilament mutation, however, would lead to chronic activation and increased autoactivation of CaMKII, resulting in aberrant, pathogenic CaMKII activity over time. We propose CaMKII activity as a potential mutation-specific therapeutic target for early, robust intervention of HCM progression. Although we acknowledge the limitations of the AC3I peptide and the reported indirect inhibition on protein kinase D, 41, 42 the lack of left ventricular remodeling indicates minimal phosphorylation of histone deacetylases by protein kinase D and subsequent activation of the hypertrophy-inducing MEF2 pathway. Moreover, although the precise specificity of the AC3I-peptide for the various states of CaMKII has not been defined, the partial, cardiac-specific reduction in autonomous CaM-KII activity (≈40%) 26 conferred by the peptide provides a realistic therapeutic goal for potential CaMKII interventions in specific HCM clinical cohorts.
To date, small molecule interventions targeted at CaMKII activity have not been successfully implemented in the management of HCM because of numerous offtarget and undesirable side effects (reviewed by Pellicena and Schulman 43 ). Thus, we investigated the mutationspecific response to available calcium-dependent interventions in clinical HCM via diltiazem-HCl, an L-type calcium channel blocker. We observed a mutation-specific response to diltiazem-HCl treatment in agreement with previous animal studies and clinical trials of HCM. 17, 29, 44, 45 Diastolic dysfunction progression was arrested in the calcium-dependent R92W animals only, a similar response to diltiazem-treated cardiac troponin T I79N animals. 44 Of note, these animals also exhibit significant calcium dysregulation that is out of proportion to the degree of cardiac remodeling. 44, 46 This functional response, however, was uncoupled from an improvement in cardiac 
remodeling, similar to a previous report in a knock-in model of a myosin binding protein C (MyBPC) HCM mutation. 45 Importantly, the animals in this study as well as those in Flenner et al 45 exhibited significant left ventricular remodeling before the onset of treatment, suggesting an inability of diltiazem-HCl to induce reversal of remodeling. This early onset of cardiac remodeling likely explains the conflicting findings in comparison with those reported by Semsarian et al, 29 whereby the authors reported blunted hypertrophic remodeling with early diltiazem-HCl in the prehypertrophic, HCM-associated MyH7 R403Q animals. We speculate this mutationdependent, incomplete reversal of pathology is likely attributable to targeting within the excitation-contraction coupling pathway upstream of the calcium dysregulation that is initiated at the myofilament.
A similar mutant gene-specific response to diltiazem-HCl in function and morphology was described in a clinical trial of prehypertrophic sarcomeric-HCM. 17, 18 The authors reported a delay of cardiac remodeling and function in MYBPC3-mutation carriers, indicating decreased left ventricular stiffness and improved diastolic function with the use of diltiazem-HCl. However, a subset of MYH7-mutation carriers did not respond to diltiazem-HCl, developing pathological hypertrophy throughout treatment. 18 We report a similar response whereby treated R92L animals exhibited a trending increase in progression of diastolic dysfunction as compared to their untreated controls.
Together, these data examining the response to differential therapeutics targeted within the calcium pathway underscore the need to define specific molecular mechanisms of disease progression. We suggest here that the early increase in CaMKII activation observed in R92W mice may modulate disease progression in other cases of calcium-dependent HCM progression. Finally, by defining a link between myofilament calcium handling and CaMKII activation, calcium release rates can be used as a tool to predict mutation-specific, downstream calcium dysregulation. With this screening method, we can potentially identify preclinical cohorts that will preferentially respond to CaMKII intervention, thereby facilitating the targeting of the natural history of disease in patients with sarcomeric HCM.
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